Impact of Brokerage Rating on Endologix, Inc.(ELGX)

Many Endologix, Inc.(ELGX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Endologix was Downgraded by Canaccord Genuity on Nov 17, 2016 to Hold, Lowers Price Target to $ 7.50 from a previous price target of $13.50 .

Company has reported several Insider transactions to the SEC, on Dec 15, 2016, Iii Thomas F Zenty (director) purchased 3,000 shares at 6.51 per share price.On Dec 15, 2016, John D Mcdermott (CEO) purchased 10,000 shares at 6.67 per share price.On Dec 15, 2016, Vaseem Mahboob (CFO) purchased 20,000 shares at 6.25 per share price.

Endologix Last issued its quarterly earnings results on Nov 1, 2016. The company reported $-0.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $-0.16. The company had revenue of $52.12 million for the quarter, compared to analysts expectations of $51.90 million. The companys revenue was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.16 EPS.

Endologix, Inc. (NASDAQ:ELGX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.89 by 9 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 4 Brokerage Firms have advised hold.

Endologix, Inc. (NASDAQ:ELGX): The mean estimate for the short term price target for Endologix, Inc. (NASDAQ:ELGX) stands at $10.39 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $16 while the lower price target estimate is at $7.

Endologix, Inc. (NASDAQ:ELGX) rose 0.15% or 0.01 points on Tuesday and made its way into the gainers of the day. After trading began at $6.75 the stock was seen hitting $6.9 as a peak level and $6.6 as the lowest level. The stock ended up at $6.77. The daily volume was measured at 766,521 shares. The 52-week high of the share price is $14.495 and the 52-week low is $4.78. The company has a market cap of $560 million.

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.

Endologix,

Share this post

Post Comment